1GDA Stock Overview
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Zevra Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.20 |
| 52 Week High | US$6.45 |
| 52 Week Low | US$3.82 |
| Beta | 1.84 |
| 1 Month Change | -20.00% |
| 3 Month Change | -21.50% |
| 1 Year Change | -9.87% |
| 3 Year Change | -46.84% |
| 5 Year Change | -77.19% |
| Change since IPO | -98.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1GDA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.0% | 3.9% | 2.0% |
| 1Y | -9.9% | -28.2% | 2.0% |
Return vs Industry: 1GDA exceeded the German Pharmaceuticals industry which returned -28.6% over the past year.
Return vs Market: 1GDA underperformed the German Market which returned 1.3% over the past year.
Price Volatility
| 1GDA volatility | |
|---|---|
| 1GDA Average Weekly Movement | 8.2% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1GDA's share price has been volatile over the past 3 months.
Volatility Over Time: 1GDA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 67 | Neil McFarlane | zevra.com |
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
Zevra Therapeutics, Inc. Fundamentals Summary
| 1GDA fundamental statistics | |
|---|---|
| Market cap | €176.83m |
| Earnings (TTM) | -€43.05m |
| Revenue (TTM) | €25.67m |
6.9x
P/S Ratio-4.1x
P/E RatioIs 1GDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1GDA income statement (TTM) | |
|---|---|
| Revenue | US$27.46m |
| Cost of Revenue | US$2.95m |
| Gross Profit | US$24.52m |
| Other Expenses | US$70.57m |
| Earnings | -US$46.05m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.10 |
| Gross Margin | 89.28% |
| Net Profit Margin | -167.69% |
| Debt/Equity Ratio | 69.1% |
How did 1GDA perform over the long term?
See historical performance and comparison